Literature DB >> 18175395

Update on the genetics of Parkinson's disease.

Thomas Gasser1.   

Abstract

Over the last few years, several genes for monogenic forms of Parkinson's disease (PD) have been mapped and/or cloned. Mutations have been identified in the gene for alpha-synuclein in rare families with dominant PD, indicating that aggregation of this protein in Lewy bodies is probably a crucial step in the molecular pathogenesis of the disorder. A much more common cause for dominant PD, mutations in the gene for leucine-rich repeat kinase 2 (LRRK2), has recently been identified. Mutations in the parkin gene, in DJ-1 and PINK1 all cause autosomal recessive parkinsonism of early onset. These genes have been implicated in the proteasomal protein degradation pathway, in the oxidative stress response and mitochondrial function. Mutations in recessive genes probably are pathogenic through loss-of-function mechanisms, suggesting that their wildtype products protect dopaminergic cells against a variety of insults. Evidence is emerging that at least some of these genes may play a direct role in the etiology of the common sporadic form of PD. Further, it is likely that the cellular pathways identified in rare monogenic variants of the disease also shed light on the molecular pathogenesis in typical sporadic PD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18175395     DOI: 10.1002/mds.21676

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  50 in total

Review 1.  Regulation of Parkin E3 ubiquitin ligase activity.

Authors:  Helen Walden; R Julio Martinez-Torres
Journal:  Cell Mol Life Sci       Date:  2012-04-19       Impact factor: 9.261

Review 2.  Redefining Parkinson's disease research using induced pluripotent stem cells.

Authors:  Jiali Pu; Houbo Jiang; Baorong Zhang; Jian Feng
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

Review 3.  Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis.

Authors:  Sharawan Yadav; Anubhuti Dixit; Sonal Agrawal; Ashish Singh; Garima Srivastava; Anand Kumar Singh; Pramod Kumar Srivastava; Om Prakash; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2012-06-27       Impact factor: 5.590

Review 4.  Juvenile parkinsonism: epidemiology, diagnosis and treatment.

Authors:  Teri R Thomsen; Robert L Rodnitzky
Journal:  CNS Drugs       Date:  2010-06       Impact factor: 5.749

5.  Neuroprotective upregulation of endogenous α-synuclein precedes ubiquitination in cultured dopaminergic neurons.

Authors:  R E J Musgrove; A E King; T C Dickson
Journal:  Neurotox Res       Date:  2010-07-09       Impact factor: 3.911

6.  Risk for Parkinson's disease among patients with osteoarthritis: a Danish cohort study.

Authors:  Kathrine Rugbjerg; Søren Friis; Thomas L Jørgensen; Beate Ritz; Lise Korbo; Jørgen H Olsen
Journal:  Mov Disord       Date:  2010-10-30       Impact factor: 10.338

7.  A PTEN translational isoform has PTEN-like activity.

Authors:  Xie Zhang; Bowei Yin; Fangfang Zhu; Guochang Huang; Hong Li
Journal:  Chin J Cancer Res       Date:  2015-10       Impact factor: 5.087

8.  Cellular repair strategies in Parkinson's disease.

Authors:  Beate Winner; Daniela M Vogt-Weisenhorn; Chichung D Lie; Ingmar Blümcke; Jürgen Winkler
Journal:  Ther Adv Neurol Disord       Date:  2009-01       Impact factor: 6.570

Review 9.  Phosphatase and tensin homologue deleted on chromosome 10: extending its PTENtacles.

Authors:  Bangyan L Stiles
Journal:  Int J Biochem Cell Biol       Date:  2008-10-02       Impact factor: 5.085

10.  Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).

Authors:  Eva Andres-Mateos; Rebeca Mejias; Masayuki Sasaki; Xiaojie Li; Brian M Lin; Saskia Biskup; Li Zhang; Rebecca Banerjee; Bobby Thomas; Lichuan Yang; Guosheng Liu; M Flint Beal; David L Huso; Ted M Dawson; Valina L Dawson
Journal:  J Neurosci       Date:  2009-12-16       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.